Neuland Labs accelerates peptide manufacturing expansion with operational module, capacity underway.
Neuland Laboratories has operationalized its first commercial peptide manufacturing module, part of a four-module expansion. The $30 million investment in module one provides 7000L reactor capacity. Module two is planned with up to 18,000L capacity. This expansion aims to meet rising customer demand and support growing peptide pipelines.
The expansion of peptide manufacturing capacity, including significant investment and planned future capacity, is a material development that is likely to have a significant impact on the company's revenue and market position.
The announcement details the operationalization of new manufacturing capacity and ongoing expansion, which is a positive development for the company's growth and ability to meet customer demand.
Neuland Laboratories has announced the acceleration of its peptide manufacturing expansion with the commencement of operations at the first of four scheduled modules at its commercial peptide manufacturing site. The company is also expanding additional capacity.
Module one, which required an investment of $30 million, provides a total reactor capacity of 7000L, including 750L for solid-phase peptide synthesis and 6250L for liquid-phase peptide synthesis. This enables flexible customer programs from small-scale to multi-kilogram quantities for complete peptide APIs, including complex and long-chain peptides, as well as commercial-scale production of crude peptides. The SPPS and LPPS reactors are housed in separate suites for parallel operation and are supported by three DAC columns (one 45 cm and two 60 cm) and two lyophilizers with 100 L and 200 L capacities.
With the foundational infrastructure for the second module already in place, Neuland anticipates beginning work ahead of the original timeline, pending finalization of customer requirements. The configuration, instrumentation, and capacity for module two are being defined in close collaboration with the anchoring customer. Module two is planned to offer an overall reactor capacity of up to 18,000 L, comprising three 5,000 L LPPS reactors, and either a 1,000 L or 2,000 L SPPS reactor, along with smaller reactors up to the 1,000 L scale. This flexible configuration will support a wide range of peptide programs and production scales.
The company notes a broadening range of partner indications beyond obesity and metabolic disease, with oncology emerging as a significant area of early-stage development. Neuland CEO & MD, Saharsh Davuluri, stated, “Our goal is to ensure we have the capacity to meet customer demand not just over the next 24 months, but over the next decade, as we deepen our strategic partnerships with leading pharma and biotech companies.”
Module one is supported by a team of nearly 212 peptide experts. This expansion follows a period of strong growth for the CDMO, with revenues increasing by 116% in its most recent quarterly results, driven by increased commercial contracts and a growing number of clinical projects. Neuland Laboratories operates three US FDA and EU GMP-compliant facilities in India, with a combined reactor capacity of approximately 1218kL, and invested in a new commercial-scale peptide facility in 2026, alongside a large, dedicated R&D process development center in Hyderabad.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under capex. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.